Background: The goal of soil-transmitted helminthiases (STH) control programmes is to eliminate STH-associated morbidity in the target population by reducing the prevalence of moderate-and heavy-intensity infections and the overall STH infection prevalence mainly through preventive chemotherapy (PC) with either albendazole or mebendazole. Endemic countries should measure the success of their control programmes through regular epidemiological assessments. We evaluated changes in STH prevalence in countries that conducted effective PC coverage for STH to guide changes in the frequency of PC rounds and the number of tablets needed.
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Background
Soil-transmitted helminths are a group of intestinal parasites that are transmitted to humans through ingestion of infective eggs or transcutaneous penetration of larvae excreted in human faeces which contaminate the soil and water sources [1] . Soil-transmitted helminthiases (STH) are among the most common neglected tropical diseases (NTDs) in developing countries. Worldwide, it is estimated that 820 million people are infected with roundworm (Ascaris lumbricoides), 460 million with whipworm (Trichuris trichiura) and 460 million with hookworms (Necator americanus and Ancylostoma duodenale) in 102 countries [2] . In 2010, these infections contributed 3.4 million disability-adjusted life-years to the global burden of disease [1] .
The World Health Organization (WHO) recommends preventive chemotherapy (PC) with albendazole or mebendazole to control STH-related morbidity alongside targeted health education and improved water and sanitation [3] . PC is the regular, coordinated administration of anthelminthic medicines to population groups at risk for STH morbidity. The target populations include preschool-age children (PSAC), school-age children (SAC), women of reproductive age (WRA) and adult groups particularly exposed to STH. The 2020 WHO goal for control of STH is to treat ≥75% of PSAC and SAC in all STH endemic countries [4] . In 2017, more than 500 million SAC (69% of total SAC in need) received PC for STH globally, with 73% of implementation units reaching 75% effective coverage [5] .
The main objective of the STH control programme is to eliminate morbidity in the target population by reducing the prevalence of moderate-and heavy-intensity infections to < 2% [3] . A meta-analysis conducted by Marocco et al. showed that after five years of PC, 80% of individuals with infections of moderate and heavy intensity were cured or remained with only light-intensity infection [6] .
Since 2010, WHO with the support of drug producers has donated albendazole or mebendazole for the control of STH. In 2018 alone, more than 485 million tablets were donated to endemic countries [5] .
The WHO manual on STH control in SAC recommends that control programmes managers collect parasitological indicators every 3-5 years of PC with effective coverage in order to measure the effect of the intervention on the health of the population at risk [4] and, eventually, to reduce the number of PC rounds if the prevalence of STH infection has reduced to a certain level using the WHO decision tree (Additional file 2) [4] .
In this study we evaluated the changes in STH prevalence from countries that conducted STH PC for ≥5 years with effective treatment coverage (that is, national treatment coverage ≥75% as defined by WHO) for SAC. These data also give an indication of expected changes in prevalence if countries conduct ≥5 years of PC, and therefore also the expected number of drugs needed by endemic countries over time.
Methods

National PC coverage data
We accessed WHO's Preventive Chemotherapy and Transmission control (PCT) databank, an open webbased database on PC implementation in 102 endemic countries [7] , to identify countries that had implemented effective coverage of PC (defined as ≥75% national coverage) among SAC for ≥5 years.
Epidemiological data reporting form
The Epidemiological Data Reporting Form (EPIRF) is a standardized form designed to collect epidemiological data on all diseases targeted by PC, namely STH, lymphatic filariasis (LF), onchocerciasis and schistosomiasis. Indicators reported include: survey type, number of rounds of PC delivered prior to survey, date of survey, number of people examined, and numbers of people diagnosed positive for each STH species and for overall STH. Countries receiving donated anthelminthic medicines are invited to periodically report to WHO any changes in the epidemiological situation using the EPIRF. We extracted baseline and impact EPIRF data from endemic countries previously identified as having achieved ≥5 years of effective coverage.
Literature search
For countries in which the EPIRF was not available we reviewed the available literature on baseline and impact assessment surveys for STH prevalence. Only surveys targeting SAC were considered. We searched official publications such as national NTD master plans and Ministry of Health survey reports as well as data published in the peer-reviewed scientific literature between 2000 and 2017. For online searches we used the words: mapping, baseline, impact assessment, soil-transmitted helminths and country names using google search and MEDLINE.
Data analysis
Studies were eligible for inclusion if, for baseline, the data were collected before the national STH control programme was initiated and, for impact assessment, the data were collected after PC was implemented for ≥5 years with effective coverage. In addition, for all studies, SAC was the study population, the information on STH prevalence overall and/or for each STH species available. From each publication identified we extracted year, type of survey, target population, prevalence of STH and of each species, number of people examined, intensity of STH infection and diagnostic tool used. For studies where prevalence was reported by species only, we calculated the prevalence of any STH infection using the following equation [4] :
Where a = prevalence of ascariasis; t = prevalence of trichuriasis and h = prevalence of hookworm infections (all expressed as a proportion).
Data were collated, cleaned, analysed and visualized using the R (Version 3.5, R core Team, Vienna, Austria) statistical program. For data in the EPIRF form, we estimated national means using weighted cluster data for each country and for each STH species. We plotted the prevalence of any STH infection and of each species before the start of PC for STH and the prevalence after ≥5 years of PC with effective coverage using pooled and weighted means. Finally, according to the WHO STH decision tree (Additional file 2) and after ≥5 years of PC with effective coverage, countries with STH prevalence < 2% should suspend PC, < 10% should conduct PC once every 2 years, and < 20% should do PC once a year. In this study, we also estimated the decrease in drug needs for countries according to the change in STH prevalence during the ≥5 years of PC. for ≥5 years and collected data before and after interventions ( Fig. 1) .
Results
Number of countries that conducted ≥5 years of PC for STH
Prevalence of STH infection at baseline before PC
Most of the baseline data were collected during 2002-2009 ( Table 1 ). The average size of the population surveyed was 8868 (range 266-22 166) and 80% of the surveys were designed to be nationally representative. Six, four and four countries reported high, moderate and low STH prevalence, respectively. Figure 2 (left column) shows the pooled prevalence by country; the cumulative prevalence was 48.9% (33.1-64.7%) for any STH, 23.2% (13.7-32.7%) for A. lumbricoides, 21.01% (9.7-32.3%) for T. trichiura and 18.2% (10.9-25.5%) for hookworm infections. (Table 1) . These surveys were conducted during 2012-2017; the average population size surveyed was 6439 (range 990-16 890). In five countries STH prevalence was moderate while in nine STH prevalence was low. The pooled prevalence was 14.3% (7.3-21.3%) for any STH, 6.9% (1.3-12.5%) for A. lumbricoides, 5.3% (1.06-9.6%) for T. trichiura and 8.1% (4.0-12.2%) for hookworm infections (Fig. 2, right column) . In countries with low-level STH prevalence at the beginning of their STH control programme, the prevalence was reduced to < 2% while countries with high prevalence moved to low or moderate prevalence (Table 1) .
Estimated reduction in number of anthelminthic tablets
For the 5 years and more of PC for STH, five countries conducted one round annually while 10 countries did semi-annual rounds. Figure 3 shows that if the 15 countries that conducted PC for ≥5 years had applied WHO thresholds for changing the frequency of PC rounds using the impact assessment results on STH infection, the number of anthelminthic tablets needed for STH PC would have reduced by an average of 36%. According to the WHO decision tree (Additional file 2), three countries would have suspended STH PC in some areas (because the STH prevalence was < 2%) while six would have decreased the frequency of PC from semi-annual to annual or biennial, and six countries would have maintained the previous frequency of PC.
Discussion
In this study we report data from 15 STH endemic countries that conducted ≥5 years of PC with effective coverage among SAC. The overall result demonstrates a reduction of any STH prevalence and of STH species prevalence overall, representing tremendous progress for these countries. Importantly, in three countries the prevalence of any STH in the follow up survey was less than 2%, meaning that they successfully eliminated STH morbidity.
A change in prevalence status implies a change in the frequency of PC rounds according to the WHO decision tree (Additional file 2). Countries with an STH prevalence < 2% after ≥5 years of PC should suspend the intervention and maintain surveillance to detect possible rebounds of prevalence, whereas countries with a prevalence of 2-10% should proceed to semi-annual PC. To maintain the gains made when scaling down or discontinuing PC for STH, the national STH control programme should ensure that the water, sanitation and hygiene (WASH) component is also implemented. A modelling study on the impact of deworming and WASH on STH transmission has shown that discontinuing PC and sustaining PC gains require continuation of WASH interventions [22] . Only by achieving Sustainable Development Goal 6, which seeks to ensure universal access to basic WASH in communities, schools and healthcare facilities by 2030, will reductions of morbidity due to STH infection and others NTDs associated with water and sanitation be sustained [23] .
Among the 15 countries included in the study, 10 are co-endemic for LF so community-based deworming was the strategy used. Most of these countries have already started scaling down mass drug administration (MDA) for LF. Three countries (Burkina Faso, Mali and Ghana) had a low STH prevalence at the beginning of the programme, but by conducting LF MDA with ivermectin and albendazole or diethylcarbamazine citrate and albendazole, STH infections were also treated. Meanwhile, in 2019, many implementation units have already stopped PC for LF and STH.
The limitations of this study are that the data used as the baseline for STH prevalence may have been collected after the start of LF elimination programmes and thus may under-evaluate the real STH prevalence before mass treatment was initiated. For countries in which we know this was true, we used survey data collected before the start of MDA for LF, as in Cameroon, where we used baseline data collected in 1987. Moreover, impact assessment surveys were never implemented in individuals who had participated also in the baseline surveys, sometimes not even in the same area, making the comparison difficult. Finally, not all surveys were nationally representative and thus did not truly reflect the status of STH endemicity in the country. Standardized implementation of impact surveys in all endemic countries would strengthen these data.
